-- 据周三提交给澳大利亚证券交易所的文件显示，Mesoblast（ASX：MSB）已完成一项针对退行性椎间盘疾病相关慢性腰痛的 rexlemestrocel-L 治疗药物的 III 期临床试验的招募目标，至少招募了 300 名患者。 这项安慰剂对照研究将随机分配患者接受单次椎间盘内注射该公司专有的同种异体间质细胞疗法或假注射，疗程为 12 个月。根据文件，该研究的主要终点是腰痛缓解程度的显著差异。 该试验的次要终点包括功能改善、生活质量提高以及停用包括阿片类药物在内的止痛药物。 该公司预计将于 2027 年年中公布初步结果。 Mesoblast 的股价在周三的交易中上涨了近 5%。
Related Articles
Asia
Willfar Information Technology's Q1 2026 Profit Rises 6%
Willfar Information Technology (SHA:688100), a 59.55%-owned subsidiary of Wasion Holdings (HKG:3393), reported 148.3 million yuan in attributable profit for the first quarter of 2026, up 6.4% from 139.4 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.Revenue fell 4.2% year on year to 531.9 million yuan, figures showed.
$HKG:3393$SHA:688100
Asia
Zhongjin Gold's 2025 Profit Jumps 46%
Zhongjin Gold's (SHA:600489) attributable profit rose 46% to 4.93 billion yuan in 2025 from 3.39 billion yuan in 2024, according to a Wednesday filing with the Shanghai bourse.Earnings per share at the non-ferrous metals miner increased to 1.02 yuan from 0.70 yuan in the previous year.Operating revenue grew 21% year over year to 79.1 billion yuan from 65.6 billion yuan.
$SHA:600489
Asia
Jinduicheng Molybdenum's Q1 Profit Jumps 33%, Revenue Rises 27%
Jinduicheng Molybdenum's (SHA:601958) net profit attributable to shareholders in the first quarter jumped 33% year on year to 901.6 million yuan, or 0.279 yuan per share, according to a Wednesday disclosure on Shanghai filing.The attributable profit a year earlier was almost 678 million yuan, or 0.210 yuan per share.Operating revenue rose 27% to 4.16 billion yuan from 3.28 billion yuan in the previous year.The Chinese molybdenum miner's shares jumped less than 7% at the close.
$SHA:601958